Grupo J Uriach S.L.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grupo J Uriach S.L.
The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.
Research suggests N95 respirators used by medical staff can be safely decontaminated at least two to three times, with hydrogen peroxide vapor the most effective decontamination method.
Cormedix prepares NDA submission for Neutrolin for prevention of catheter-related blood stream infections, aiming to become the third approval under the US FDA’s Limited Population Pathway.
Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs
A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma.
- Other Names / Subsidiaries
- Palau Pharma S.A.
- LABOREST Italia S.p.A.
- J. Uriach y Compañía, S.A.
- Uriach OTC, S.L.
- Corporacion J. Uriach, S.A.
- Casa Pronat S.L.